FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079722746> ?p ?o ?g. }

• W2079722746 endingPage "234" @default.
• W2079722746 startingPage "213" @default.
• W2079722746 abstract "To illustrate the process of addressing adverse preclinical findings (APFs) as outlined in the first part of this review, a number of cases with unexpected APF in toxicity studies with drug candidates is discussed in this second part. The emphasis is on risk characterization, especially regarding the mode of action (MoA), and risk evaluation regarding relevance for man. While severe APFs such as retinal toxicity may turn out to be of little human relevance, minor findings particularly in early toxicity studies, such as vasculitis, may later pose a real problem. Rodents are imperfect models for endocrine APFs, non-rodents for human cardiac effects. Liver and kidney toxicities are frequent, but they can often be monitored in man and do not necessarily result in early termination of drug candidates. Novel findings such as the unusual lesions in the gastrointestinal tract and the bones presented in this review can be difficult to explain. It will be shown that well known issues such as phospholipidosis and carcinogenicity by agonists of peroxisome proliferator-activated receptors (PPAR) need to be evaluated on a case-by-case basis. The latter is of particular interest because the new PPAR α and dual α/γ agonists resulted in a change of the safety paradigm established with the older PPAR α agonists. General toxicologists and pathologists need some understanding of the principles of genotoxicity and reproductive toxicity testing. Both types of preclinical toxicities are major APF and clinical monitoring is difficult, generally leading to permanent use restrictions." @default.
• W2079722746 created "2016-06-24" @default.
• W2079722746 creator A5003947485 @default.
• W2079722746 creator A5009150373 @default.
• W2079722746 creator A5049125759 @default.
• W2079722746 creator A5080735724 @default.
• W2079722746 creator A5089621962 @default.
• W2079722746 date "2010-01-01" @default.
• W2079722746 modified "2023-09-25" @default.
• W2079722746 title "Successful Drug Development Despite Adverse Preclinical Findings Part 2: Examples" @default.
• W2079722746 cites W10452794 @default.
• W2079722746 cites W1496205825 @default.
• W2079722746 cites W1795186414 @default.
• W2079722746 cites W1965349553 @default.
• W2079722746 cites W1965555285 @default.
• W2079722746 cites W1966573424 @default.
• W2079722746 cites W1969138515 @default.
• W2079722746 cites W1970191094 @default.
• W2079722746 cites W1973461464 @default.
• W2079722746 cites W1977041568 @default.
• W2079722746 cites W1979591782 @default.
• W2079722746 cites W1983774773 @default.
• W2079722746 cites W1984527092 @default.
• W2079722746 cites W1988707549 @default.
• W2079722746 cites W1988805205 @default.
• W2079722746 cites W1991120280 @default.
• W2079722746 cites W1992868326 @default.
• W2079722746 cites W2001709043 @default.
• W2079722746 cites W2003418600 @default.
• W2079722746 cites W2003732689 @default.
• W2079722746 cites W2004445015 @default.
• W2079722746 cites W2010282151 @default.
• W2079722746 cites W2014450090 @default.
• W2079722746 cites W2018572773 @default.
• W2079722746 cites W2020396120 @default.
• W2079722746 cites W2020780267 @default.
• W2079722746 cites W2024180226 @default.
• W2079722746 cites W2024945446 @default.
• W2079722746 cites W2030210749 @default.
• W2079722746 cites W2031309744 @default.
• W2079722746 cites W2032279027 @default.
• W2079722746 cites W2032918308 @default.
• W2079722746 cites W2033800146 @default.
• W2079722746 cites W2041408150 @default.
• W2079722746 cites W2046081075 @default.
• W2079722746 cites W2046264770 @default.
• W2079722746 cites W2049619600 @default.
• W2079722746 cites W2049947428 @default.
• W2079722746 cites W2055066000 @default.
• W2079722746 cites W2055899886 @default.
• W2079722746 cites W2056205741 @default.
• W2079722746 cites W2056423868 @default.
• W2079722746 cites W2058830397 @default.
• W2079722746 cites W2060635573 @default.
• W2079722746 cites W2060937998 @default.
• W2079722746 cites W2066252948 @default.
• W2079722746 cites W2067088354 @default.
• W2079722746 cites W2068812539 @default.
• W2079722746 cites W2071979182 @default.
• W2079722746 cites W2072689861 @default.
• W2079722746 cites W2073931543 @default.
• W2079722746 cites W2073976519 @default.
• W2079722746 cites W2075519015 @default.
• W2079722746 cites W2075739694 @default.
• W2079722746 cites W2077728603 @default.
• W2079722746 cites W2079730447 @default.
• W2079722746 cites W2079872539 @default.
• W2079722746 cites W2080086479 @default.
• W2079722746 cites W2081161427 @default.
• W2079722746 cites W2081764664 @default.
• W2079722746 cites W2083980783 @default.
• W2079722746 cites W2084141124 @default.
• W2079722746 cites W2085190182 @default.
• W2079722746 cites W2087101821 @default.
• W2079722746 cites W2088777383 @default.
• W2079722746 cites W2089320077 @default.
• W2079722746 cites W2090419653 @default.
• W2079722746 cites W2091354650 @default.
• W2079722746 cites W2092728776 @default.
• W2079722746 cites W2095225035 @default.
• W2079722746 cites W2095649122 @default.
• W2079722746 cites W2096045098 @default.
• W2079722746 cites W2100610562 @default.
• W2079722746 cites W2101535700 @default.
• W2079722746 cites W2103105948 @default.
• W2079722746 cites W2106061936 @default.
• W2079722746 cites W2106779394 @default.
• W2079722746 cites W2107917412 @default.
• W2079722746 cites W2109211391 @default.
• W2079722746 cites W2109628662 @default.
• W2079722746 cites W2109632370 @default.
• W2079722746 cites W2114606262 @default.
• W2079722746 cites W2115825840 @default.
• W2079722746 cites W2116015889 @default.
• W2079722746 cites W2120009233 @default.
• W2079722746 cites W2121153797 @default.
• W2079722746 cites W2121716650 @default.
• W2079722746 cites W2123529306 @default.

• next